USANA HEALTH SCIENCES INC
For the period ended Mar 30, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 30, 2024 · Filed May 7, 2024
USNA$13.10-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 30,2024 | April 1,2023 | |
| Cash flows from operating activities | ||
| Net earnings | $16,537 | $18,383 |
| Adjustments to reconcile net earnings to net cash provided by (used in) operating activities | ||
| Depreciation and amortization | 3,158 | 3,299 |
| Right-of-use asset amortization | 1,926 | 1,925 |
| (Gain) loss on sale of property and equipment | 405 | — |
| Equity-based compensation expense | 3,669 | 3,608 |
| Deferred income taxes | 2,547 | 3,557 |
| Inventory write-down | 934 | 2,284 |
| Changes in operating assets and liabilities: | ||
| Inventories | (1,801) | (78) |
| Prepaid expenses and other assets | (5,108) | (5,205) |
| Accounts payable | (1,718) | (246) |
| Other liabilities | (2,866) | (14,694) |
| Net cash provided by (used in) operating activities | 17,683 | 12,833 |
| Cash flows from investing activities | ||
| Payments for net investment hedge | (870) | (1,271) |
| Proceeds from sale of property and equipment | 3 | — |
| Purchases of property and equipment | (3,201) | (2,107) |
| Net cash provided by (used in) investing activities | (4,068) | (3,378) |
| Cash flows from financing activities | ||
| Repurchase of common stock | (9,444) | — |
| Borrowings on line of credit | 537 | — |
| Payments related to tax withholding for net-share settled equity awards | (3,039) | (2,861) |
| Payments for contingent consideration | — | (338) |
| Net cash provided by (used in) financing activities | (11,946) | (3,199) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (3,809) | 790 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (2,140) | 7,046 |
| Cash, cash equivalents, and restricted cash at beginning of period | 333,246 | 291,320 |
| Cash, cash equivalents, and restricted cash at end of period | $331,106 | $298,366 |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | ||
| Cash and cash equivalents | $328,336 | $295,454 |
| Restricted cash included in other assets | 2,770 | 2,912 |
| Total cash, cash equivalents, and restricted cash | $331,106 | $298,366 |
| Supplemental disclosures of cash flow information | ||
| Cash paid during the period for: | ||
| Interest | $24 | $2 |
| Income taxes | 9,100 | 10,182 |
| Cash received during the period for: | ||
| Income tax refund | — | 517 |
| Non-cash investing and financing activities: | ||
| Right-of-use assets obtained in exchange for lease obligations | 167 | 1,806 |
| Accrued purchases of property and equipment | 83 | 368 |
| Accrued excise tax for repurchase of common stock | 39 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.